Effect of Saccharomyces cerevisiae strain UFMG A-905 in experimental model of inflammatory bowel disease-Reference-Cited by-同舟云学术

Effect of Saccharomyces cerevisiae strain UFMG A-905 in experimental model of inflammatory bowel disease

Published:2015-12-01 Issue:6 Volume:6 Page:807-815
ISSN:1876-2883
Container-title:Beneficial Microbes
language:en
Short-container-title:Beneficial Microbes

Author:

Tiago F.C.P.¹,Porto B.A.A.¹,Ribeiro N.S.¹,Moreira L.M.C.¹,Arantes R.M.E.²,Vieira A.T.³,Teixeira M.M.³,Generoso S.V.⁴,Nascimento V.N.⁴,Martins F.S.¹,Nicoli J.R.¹

Affiliation:

1. Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Avenida Presidente Antônio Carlos 6627, C.P. 486, Pampulha – Campus UFMG, 31270-901, Belo Horizonte, MG, Brazil

2. Department of General Pathology, Institute of Biological Sciences, Federal University of Minas Gerais, Avenida Presidente Antônio Carlos 6627, C.P. 486, Pampulha – Campus UFMG, 31270-901, Belo Horizonte, MG, Brazil

3. Department of Biochemistry and Immunology, Institute of Biological Sciences, Federal University of Minas Gerais, Avenida Presidente Antônio Carlos 6627, C.P. 486, Pampulha – Campus UFMG, 31270-901, Belo Horizonte, MG, Brazil

4. School of Pharmacy, Federal University of Minas Gerais, Avenida Presidente Antônio Carlos 6627, C.P. 486, Pampulha – Campus UFMG, 31270-901, Belo Horizonte, MG, Brazil

Abstract

In the present study, the protective potential of Saccharomyces cerevisiae strain UFMG A-905 was evaluated in a murine model of acute ulcerative colitis (UC). Six groups of Balb/c mice were used: not treated with yeast and not challenged with dextran sulphate sodium (DSS) (control); treated with S. cerevisiae UFMG A-905 (905); treated with the non-probiotic S. cerevisiae W303 (W303); challenged with DSS (DSS); treated with S. cerevisiae UFMG A-905 and challenged with DSS (905 + DSS); and treated with S. cerevisiae W303 and challenged with DSS (W303 + DSS). Seven days after induction of UC, mice were euthanised to remove colon for enzymatic, immunological, and histopathological analysis. In vivo intestinal permeability was also evaluated. An improvement of clinical manifestations of experimental UC was observed only in mice of the 905 + DSS group when compared to animals from DSS and W303 + DSS groups. This observation was confirmed by histological and morphometrical data and determination of myeloperoxidase and eosinophil peroxidase activities, intestinal permeability and some pro-inflammatory cytokines. S. cerevisiae UFMG A-905 showed to be a potential alternative treatment for UC when used in an experimental animal model of the disease.

Publisher

Wageningen Academic Publishers

Subject

Microbiology (medical),Microbiology

Link

https://www.wageningenacademic.com/doi/pdf/10.3920/BM2015.0018

Reference36 articles.

1. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse

2. VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

3. Treatment of hepatic encephalopathy with metronidazole.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Functional Bread Fermented with Saccharomyces cerevisiae UFMG A-905 Prevents Allergic Asthma in Mice;Current Developments in Nutrition;2024-04

2. Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease;Intestinal Research;2024-01-31

3. The Mechanism of Important Components in Canine Fecal Microbiota Transplantation;Veterinary Sciences;2022-12-14

4. ROS-responsive hyaluronic acid hydrogel for targeted delivery of probiotics to relieve colitis;International Journal of Biological Macromolecules;2022-12

5. Dose–Response Effect of Saccharomyces cerevisiae UFMG A-905 on the Prevention of Asthma in an Animal Model;Probiotics and Antimicrobial Proteins;2022-11-29